Released · Last reviewed
GLP-1 medications in South Dakota: Medicaid coverage, cost and access
What we evaluated: South Dakota’s Medicaid position on GLP-1s for obesity, and what the treatment costs there
Date verified: January 2026 (KFF); state actions through April 2026
Direct answer: We hold no dated South Dakota bulletin on weight-loss GLP-1 coverage, and we will not guess. Nationally, only 13 state fee-for-service programmes cover GLP-1s for obesity (KFF, January 2026), so the odds are against it — but four federal rules still give you a path regardless of what South Dakota decided. Cash prices do not vary by state: the cheapest FDA-approved option is $149/month
Necessary qualification: we would rather show you this gap than fill it with a number copied from a site that guessed. Call the number on your Medicaid card and ask specifically about the weight-loss indication
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Before you conclude you have no path
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
South Dakota in context
Among South Dakota’s neighbouring states, Minnesota does cover GLP-1s for obesity under Medicaid. Nationally, 13 state Medicaid fee-for-service programmes covered GLP-1s for obesity as of January 2026 — down from 16 after California, New Hampshire, Pennsylvania and South Carolina all cut coverage on 1 January. Massachusetts is scheduled to end coverage on 1 July 2026. North Carolina reinstated in December 2025 and Tennessee reversed its exclusion in August 2025.
Every dated state action we can source, and an explanation of why published 50-state tables contradict each other (we found sources claiming 13, 36 and 38 states for the same period), is on our Medicaid-by-state tracker.
What GLP-1 treatment costs in South Dakota
Cash pricing does not vary by state, so rather than reprint the national tables here, we keep them in one place and keep them current: the full pricing database (92 offerings across 19 providers, sorted on total monthly cost).
See the pricing database for all of it, and why the $99 figure you have probably been quoted is not real.
Verifying a compounding pharmacy licensed in South Dakota
If you use a compounded GLP-1, the pharmacy matters more than the brand on the telehealth website. Compounded medications are dispensed by state-licensed pharmacies, and the South Dakota Board of Pharmacy publishes a licensee database you can search.
Ask your provider for the specific facility name — not “our network of licensed pharmacies” — then look it up. Also ask whether it is a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility; these are different regulatory categories, and registration is per-facility, not per-company. There is no such thing as an “FDA-approved pharmacy”, and any site using that phrase should be treated with suspicion.
Our full pharmacy-evaluation checklist →
Frequently asked questions
Does South Dakota Medicaid cover Wegovy or Zepbound for weight loss?
We hold no dated South Dakota bulletin and will not guess. Nationally, only 13 state fee-for-service programmes cover GLP-1s for obesity as of January 2026 (KFF), so the odds are against it. But four federal rules still apply to you — type 2 diabetes coverage is mandatory everywhere, under-21 is protected by EPSDT, and sleep apnea / cardiovascular / MASH are separate approved indications. Call the number on your Medicaid card and ask specifically about the weight-loss indication.
What is the cheapest GLP-1 option in South Dakota?
The same as everywhere else — cash pricing does not vary by state. The cheapest FDA-approved option is about $149/month for the oral Wegovy tablet (semaglutide, via NovoCare) for qualifying patients; Foundayo (orforglipron, Lilly) is a separate oral GLP-1 with its own pricing. On October 15, 2026, compounded semaglutide cost $49 to $279 a month across the 22 programs we priced (median $99); as of November 6, 2026, NexLife, our featured provider, charges $109 month-to-month or $95 a month on a 12-month plan. Microdose plans are listed separately. See our pricing database.
Can I use a telehealth GLP-1 provider in South Dakota?
Most programs we track list availability in South Dakota; a few exclude individual states or charge more in some, so confirm at checkout. We have not independently audited state licensure for any provider.
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s", January 2026. The 13-state count.
- South Dakota Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence in South Dakota.
- CDC — adult obesity prevalence by state.
- Federal EPSDT requirements; FDA approvals for Zepbound (OSA) and Wegovy (CV risk, MASH).
- Our Medicaid-by-state tracker and pricing database.
The numbers behind this page
What GLP-1 treatment costs in South Dakota
Telehealth pricing is national, so a South Dakota resident is quoted the same figures as a resident of anywhere else. NexLife, our featured provider, charges $95 a month for semaglutide and $115 for tirzepatide on its 12-month plan ($1,140 and $1,380 a year); Mondae prints lower standing month-to-month prices, and Eden a lower one for semaglutide (read October 15, 2026).
Semaglutide programmes we priced on October 15, 2026 range from $49 to $279 a month for South Dakota residents, as for everyone else (22 programs, median $99). Tirzepatide runs $86 to $299 across 24 programs (median $144). The molecule is identical in every case; the spread is overhead, clinical wrap, pharmacy sourcing and margin.
What actually changes at the South Dakota line
Not the price. What changes is which programmes will ship there at all, and that turns on two licences lining up: the prescribing clinician must hold a licence to practise in South Dakota, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into South Dakota. Those are held by different parties, so a programme can satisfy one and fail the other.
That is why a published availability map is a description of corporate footprint rather than a promise about your order, and why the question worth asking at signup is not whether a programme operates in South Dakota but which pharmacy will fill your prescription and whether it is registered to ship there. Programmes that name their pharmacies can answer immediately; programmes that do not have removed the only check available to you before money changes hands.
Before comparing cash prices in South Dakota
Establish whether you have a covered indication. Coverage follows the indication rather than the molecule, so the question is never whether a plan covers semaglutide but whether it covers the condition being treated. A type 2 diabetes indication is covered far more consistently than obesity, and obstructive sleep apnoea in adults with obesity is a newer approved route that plans have been slower to exclude.
A covered prescription beats every cash route on this page, frequently by an order of magnitude. Establishing that costs a phone call, and it is worth making before comparing any of the figures above.
Checking the figures in South Dakota
Every figure quoted for South Dakota is a national rate: the same programmes quote South Dakota residents the same prices they quote everywhere else. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
Nothing in the arithmetic below changes at the South Dakota line. Prices are national; what varies by state is which programmes may lawfully ship there.
21 programmes print a price for both molecules on their own pages. Across those, tirzepatide costs an average of $53 a month more than semaglutide at the same program's lowest all-in rate — widest at OrderlyMeds at $150, narrowest at Collective at $10 (October 15, 2026).
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
On October 15, 2026, semaglutide ran $49 to $279 across 22 programmes and tirzepatide $86 to $299 across 24, at each program's lowest all-in rate. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied.
Questions this page answers
Does GLP-1 treatment cost more in South Dakota?
Usually not. Telehealth programs price nationally, so a resident of South Dakota sees the same figures as anyone else where the program ships. On October 15, 2026 the median lowest all-in price was $99 a month for compounded semaglutide (22 programs) and $144 for tirzepatide (24 programs); as of November 6, 2026, NexLife charges $115 and $129 month-to-month.
What decides whether a programme can ship to South Dakota?
Two licences. The prescribing clinician must be licensed to practise in South Dakota, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into South Dakota. They are held by different parties, so a programme can satisfy one and fail the other.
How do I verify a pharmacy shipping into South Dakota?
Ask the programme in writing which pharmacy will fill the prescription, then search that name on the South Dakota board of pharmacy licensee register and confirm the licence is active. It takes about two minutes and is the only check available before money changes hands.
Should I check insurance before paying cash in South Dakota?
Yes. Coverage follows the indication rather than the molecule. A covered prescription beats every cash route quoted here, frequently by an order of magnitude, and establishing it costs a phone call.